Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Total Liabilities (2019 - 2025)

Historic Total Liabilities for Eton Pharmaceuticals (ETON) over the last 7 years, with Q3 2025 value amounting to $81.4 million.

  • Eton Pharmaceuticals' Total Liabilities rose 30978.85% to $81.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $81.4 million, marking a year-over-year increase of 30978.85%. This contributed to the annual value of $51.7 million for FY2024, which is 21786.88% up from last year.
  • As of Q3 2025, Eton Pharmaceuticals' Total Liabilities stood at $81.4 million, which was up 30978.85% from $77.7 million recorded in Q2 2025.
  • Over the past 5 years, Eton Pharmaceuticals' Total Liabilities peaked at $81.4 million during Q3 2025, and registered a low of $9.2 million during Q2 2021.
  • For the 5-year period, Eton Pharmaceuticals' Total Liabilities averaged around $24.4 million, with its median value being $14.2 million (2023).
  • In the last 5 years, Eton Pharmaceuticals' Total Liabilities tumbled by 770.46% in 2021 and then skyrocketed by 32326.13% in 2025.
  • Quarter analysis of 5 years shows Eton Pharmaceuticals' Total Liabilities stood at $9.8 million in 2021, then grew by 21.53% to $12.0 million in 2022, then skyrocketed by 36.07% to $16.3 million in 2023, then soared by 217.87% to $51.7 million in 2024, then soared by 57.43% to $81.4 million in 2025.
  • Its Total Liabilities stands at $81.4 million for Q3 2025, versus $77.7 million for Q2 2025 and $59.6 million for Q1 2025.